Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Müller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M; Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien J, et al. Among authors: schott h. J Clin Oncol. 2004 Apr 1;22(7):1188-94. doi: 10.1200/JCO.2004.06.155. Epub 2004 Feb 23. J Clin Oncol. 2004. PMID: 14981107 Clinical Trial.
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Atzpodien J, Kirchner H, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jürgenson S, Wandert T, Patzelt T, Reitz M. Atzpodien J, et al. Among authors: schott h. Br J Cancer. 2001 Oct 19;85(8):1130-6. doi: 10.1054/bjoc.2001.2076. Br J Cancer. 2001. PMID: 11710825 Free PMC article. Clinical Trial.
Cytotoxic and apoptotic effects of novel heterodinucleoside phosphates consisting of 5-fluorodeoxyuridine and Ara-C in human cancer cell lines.
Saiko P, Bauer W, Horvath Z, Hoechtl T, Grusch M, Illmer C, Madlener S, Krupitza G, Mader RM, Schott H, Fritzer-Szekeres M, Szekeres T. Saiko P, et al. Among authors: schott h. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1507-11. doi: 10.1081/NCN-200027723. Nucleosides Nucleotides Nucleic Acids. 2004. PMID: 15571287
Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
Maier S, Strasser S, Saiko P, Leisser C, Sasgary S, Grusch M, Madlener S, Bader Y, Hartmann J, Schott H, Mader RM, Szekeres T, Fritzer-Szekeres M, Krupitza G. Maier S, et al. Among authors: schott h. Apoptosis. 2006 Mar;11(3):427-40. doi: 10.1007/s10495-006-4066-x. Apoptosis. 2006. PMID: 16538382
Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells.
Saiko P, Horvath Z, Illmer C, Madlener S, Bauer W, Hoechtl T, Erlach N, Grusch M, Krupitza G, Mader RM, Jaeger W, Schott H, Agarwal RP, Fritzer-Szekeres M, Szekeres T. Saiko P, et al. Among authors: schott h. Leuk Res. 2005 Jul;29(7):785-91. doi: 10.1016/j.leukres.2004.12.015. Epub 2005 Feb 19. Leuk Res. 2005. PMID: 15927674
5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
Strasser S, Maier S, Leisser C, Saiko P, Madlener S, Bader Y, Bernhaus A, Gueorguieva M, Richter S, Mader RM, Wesierska-Gadek J, Schott H, Szekeres T, Fritzer-Szekeres M, Krupitza G. Strasser S, et al. Among authors: schott h. Differentiation. 2006 Dec;74(9-10):488-98. doi: 10.1111/j.1432-0436.2006.00082.x. Differentiation. 2006. PMID: 17177846
387 results